Dana-Farber Cancer Institute;ESMO 2023;neuroendocrine cancer;Cabozantinib ;clinical trial;Cancer

Dual-action drug produces positive results in patients with advanced neuroendocrine tumors, trial finds

[ad_1] Newswise — Boston – A drug that simultaneously strikes cancer cells’ growth circuits and pipeline to the bloodstream produced…